Veniti said today it inked a limited global distribution deal with Boston Scientific (NYSE:BSX) for its Vici venous stent. The companies did not release details on which regions Boston Scientific would distribute the stent in or any financial terms of the deal. “The Vici venous stent is widely recognized as state-of-the-art technology for venous stents and physicians […]
Veniti said today that Boston Scientific (NYSE:BSX) put up $25 million for its Series D round, which it plans to use to back a clinical trial of its Vici venous stent. Veniti’s 200-patient, 60-month Virtus trial, run under an investigational device exemption from the FDA, is a single-arm safety & efficacy study with a main safety endpoint of major adverse […]
Veniti founder, president & CEO Sean Morris is on the march, looking to take over venous disease treatment with a suit of specialized devices that he hopes will knock out their more generic forebears.
Veniti, formed in 2009, specializes in devices for the venous anatomy, an arena often covered in a larger medical device company’s vascular devices business.
SonoSite (NSDQ:SONO) CFO Marcus Smith stands to pull down more than $3 million now that he’s retired from the Bothell, Wash.-based ultrasound device maker.
The company said Smith’s resignation, which went into effect yesterday, was to pursue other opportunities.
The former Philips Medical Systems exec will end up with more than $3 million in the bank after he receives all of his separation benefits, according to a company filing with the SEC.
Medtronic Inc. (NYSE:MDT) is looking to drum up $1 billion through a debt offering.
The Fridley, Minn.-based medical device giant announced a registered offering of $500 million worth of its 2.625 percent senior notes, due 2016, and $500 million of its 4.125 percent senior notes due in 2021.